Categories

AstraZeneca announces additional approval for ENHERTU® (fam-trastuzumab deruxtecan-nxki)

AstraZeneca recently announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.1 ENHERTU has Boxed […]

Read More No Comments

Order your copy today! Free Pocket-sized Version of NCCN Guidelines for Prostate Cancer

Read More No Comments

NCCN Flash 2nd Quarter Updates

This report contains NCCN Flash Updates™ relative to the second quarter of 2015, listed in chronological order with the most recent updates first.

Read More No Comments